AFP and esophageal squamous cell carcinoma: Cancer targets for these clinical stage–engineered TCR T cells include: preferentially expressed antigen in melanoma (PRAME), New York esophageal squamous cell carcinoma 1 (NY-ESO), melanoma-associated antigen (MAGE) A4, MAGE A3/A6, MAGE A10 and alpha-fetoprotein (AFP) [276].